Sloan Kettering’s Clinical Trial EHR Integration: A New Era Unveiled
In an era in which the White House Office of Science and Technology Policy emphasizes the need for a...
ICON Survey Stresses Combo Therapies in Obesity Care
ICON plc conducted an industry survey of over 100 professionals engaged in obesity-related clinical research, revealing expectations for the...
Gilead Evoke-01 Phase 3 Study: Critical Update Issued
Gilead Sciences, Inc. announced that the Phase 3 EVOKE-01 study, which evaluated Trodelvy® (sacituzumab govitecan-hziy; SG) against docetaxel in...
8-Year Data: BMS Opdivo & Yervoy Outperform in RCC Survival
Bristol Myers Squibb (BMS) announced that the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) continues to show significant long-term...
Opdivo & Cabometyx Show 4-Year Benefits in RCC Trial
Opdivo® (nivolumab) in combination with CABOMETYX® (cabozantinib) has shown continued benefits in the first-line treatment of advanced renal cell...
KoNECT And Its Remarkable Role in Korean Clinical Trials
In today’s interview, we’re speaking with Dr. In-seok Park, Ph.D., the esteemed President of KoNECT. Dr. Park, who assumed...
FDA Needs To Release ClinicalTrials.gov Guidance Now
The 2024 Clinical Trials Transformation Initiative (CTTI) report, drawing on a broad spectrum of responses from diverse stakeholders in...
Arcus & Gilead: Quemliclustat Regimens Show Hope in Pancreatic Cancer
Arcus Biosciences, Inc. announced promising overall survival data from the ARC-8 Phase 1b trial, co-developed with Gilead Sciences. The...
Latest Clinical Trial Tech Emerges: A Medidata NEXT Insight
At the 2023 Medidata NEXT conference, prominent figures like Michelle Hartman from South Broward Research, Adam Kinsey from Merck,...
Takeda’s HYQVIA Wins FDA Approval for CIDP Therapy
Takeda has announced that the FDA has approved HYQVIA® for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) as...